Branded

With a ​​​​​​​prescription from their healthcare provider, Rite Aid customers have increased access to Paxlovid and Molnupiravir.

Ztal​​​​​​​my is the first and only FDA-approved treatment for seizures associated with CDKL5 deficiency disorder in patients aged 2 years old and older, the company said.

Triumeq, the first dispersible single-tablet regimen containing dolutegravir, increases age-appropriate treatment options for children living with HIV, the company said.

The expanded indication for the first and only complete long-acting HIV regimen provides an option with as few as six dosing days per year for virologically suppressed young people living with HIV.

Ozempic will be available in 0.5 mg, 1 mg and 2 mg to help people with Type 2 diabetes reach their blood sugar (A1C) goal, including those with a higher A1C who have been unable to meet their A1C target.

Tlando is an oral treatment for testosterone replacement therapy indicated for conditions associated with a deficiency or absence of endogenous testosterone or hypogonadism in adult males.

Fintepla is now approved for the treatment of seizures associated with Lennox-Gastaut syndrome in patients two years of age and older.

Xelstrym is a transdermal amphetamine patch used to treat ADHD.

The Food and Drug Administration has approved Keytruda, Merck's anti-PD-1 therapy, as a single agent for the treatment of some patients with advanced endometrial carcinoma.

The approval is the first indication for Rinvoq in gastroenterology, the company said.

Lynparza is now approved as an adjuvant treatment for patients with germline BRCA-mutated HER2-negative high risk early breast cancer.

Carvykti provides a treatment for adults with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.